Pharmacy Times articleshttps://www.pharmacytimes.com/newsPharmacy Times articles© 2026 MJH Life Sciences™ and Pharmacy Times. All rights reserved.Mon, 08 Jun 2026 01:09:28 +00005en-us14447https://www.pharmacytimes.com/newshttps://www.pharmacytimes.com/logo.webphttps://www.pharmacytimes.com/view/ada-2026-why-some-t2d-patients-don-t-respond-to-glp-1-ras-and-what-pharmacists-should-screen-forhttps://www.pharmacytimes.com/view/ada-2026-why-some-t2d-patients-don-t-respond-to-glp-1-ras-and-what-pharmacists-should-screen-for<![CDATA[Expert Lance Sloan, MD, discusses CATALYST trial findings on mifepristone, glucagon-like peptide-1 receptor agonist (GLP-1 RA) resistance, and screening for hypercortisolism in uncontrolled type 2 diabetes (T2D).]]>Sun, 07 Jun 2026 20:24:04 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-semaglutide-add-on-reduces-glycemic-burden-cardiometabolic-risk-in-older-adults-with-t2dhttps://www.pharmacytimes.com/view/ada-2026-semaglutide-add-on-reduces-glycemic-burden-cardiometabolic-risk-in-older-adults-with-t2d<![CDATA[Adding semaglutide to existing regimens in older adults with inadequately controlled T2D significantly reduced HbA1c, fasting blood glucose, body weight, and blood pressure.]]>Sun, 07 Jun 2026 15:36:51 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-pharmacist-ce-programs-may-reduce-clinical-inertia-in-type-2-diabetes-https://www.pharmacytimes.com/view/ada-2026-pharmacist-ce-programs-may-reduce-clinical-inertia-in-type-2-diabetes-<![CDATA[Targeted diabetes education improved pharmacists' confidence and competence in addressing clinical inertia, with survey data identifying leading causes of delayed treatment intensification in type 2 diabetes.]]>Sun, 07 Jun 2026 14:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-earlier-glp-1-and-sglt-2-use-recommended-from-diabetes-diagnosis-expert-sayshttps://www.pharmacytimes.com/view/ada-2026-earlier-glp-1-and-sglt-2-use-recommended-from-diabetes-diagnosis-expert-says<![CDATA[John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.]]>Sun, 07 Jun 2026 03:46:50 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/new-research-suggests-bempedoic-acid-outperforms-ezetimibe-for-heart-health-in-patients-with-type-2-diabeteshttps://www.pharmacytimes.com/view/new-research-suggests-bempedoic-acid-outperforms-ezetimibe-for-heart-health-in-patients-with-type-2-diabetes<![CDATA[Real-world ADA 2026 data shows bempedoic acid add-on lowers major heart risks in type 2 diabetes more than ezetimibe, despite smaller LDL drops.]]>Sat, 06 Jun 2026 15:28:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-pharmacist-integration-into-refill-workflows-reduces-provider-burnout-and-catches-safety-riskshttps://www.pharmacytimes.com/view/ada-2026-pharmacist-integration-into-refill-workflows-reduces-provider-burnout-and-catches-safety-risks<![CDATA[Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.]]>Sat, 06 Jun 2026 14:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-weight-loss-exploring-the-renal-and-anti-inflammatory-benefits-of-high-dose-semaglutidehttps://www.pharmacytimes.com/view/beyond-weight-loss-exploring-the-renal-and-anti-inflammatory-benefits-of-high-dose-semaglutide<![CDATA[High-dose semaglutide shows improved kidney markers and lowers inflammation in obesity without diabetes, suggesting benefits beyond weight loss.]]>Sat, 06 Jun 2026 01:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-the-2026-ada-standards-a-pharmacist-s-guide-to-cardiorenal-risk-reductionhttps://www.pharmacytimes.com/view/ada-2026-the-2026-ada-standards-a-pharmacist-s-guide-to-cardiorenal-risk-reduction<![CDATA[Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.]]>Sat, 06 Jun 2026 00:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/oncology-pulsepoint-metastatic-crpc-asco-living-guidelines-updateshttps://www.pharmacytimes.com/view/oncology-pulsepoint-metastatic-crpc-asco-living-guidelines-updates<![CDATA[Vince Sung, PharmD, MBA, BCOP, BCPS, discusses the clinical implications of the updated prostate cancer guidelines. ]]>Fri, 05 Jun 2026 19:04:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/-you-have-to-be-a-little-bit-creative-alyson-myers-on-caring-for-patients-with-type-1-diabetes-living-paycheck-to-paycheckhttps://www.pharmacytimes.com/view/-you-have-to-be-a-little-bit-creative-alyson-myers-on-caring-for-patients-with-type-1-diabetes-living-paycheck-to-paycheck<![CDATA[Alyson Myers, MD, explains why expanded telehealth access, technology equity, and pharmacist partnerships are essential — not optional.]]>Fri, 05 Jun 2026 18:03:12 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/it-takes-a-village-bringing-cell-gene-therapy-to-patientshttps://www.pharmacytimes.com/view/it-takes-a-village-bringing-cell-gene-therapy-to-patients<![CDATA[A panel of clinical pharmacists meets to discuss the complex process of operationalizing cell and gene therapy at an academic medical center.]]>Fri, 05 Jun 2026 18:02:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/adults-with-schizophrenia-remain-stable-when-transitioning-from-atypical-antipsychotic-to-cobenfyhttps://www.pharmacytimes.com/view/adults-with-schizophrenia-remain-stable-when-transitioning-from-atypical-antipsychotic-to-cobenfy<![CDATA[Both slow and fast transition periods were safe and effective, with minimal adverse events.]]>Fri, 05 Jun 2026 17:05:36 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/pharmacist-led-refill-authorization-reduces-provider-burden-in-endocrinology-https://www.pharmacytimes.com/view/pharmacist-led-refill-authorization-reduces-provider-burden-in-endocrinology-<![CDATA[A pharmacist-led refill authorization program in endocrinology eliminated 3750 refill requests from provider in-baskets in 2025. ]]>Fri, 05 Jun 2026 15:13:23 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/brain-inflammation-may-not-drive-persistent-long-covid-symptoms-new-imaging-study-findshttps://www.pharmacytimes.com/view/brain-inflammation-may-not-drive-persistent-long-covid-symptoms-new-imaging-study-finds<![CDATA[PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.]]>Fri, 05 Jun 2026 14:29:14 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-clinical-pharmacist-led-group-sessions-show-promise-for-hypoglycemia-prevention-in-older-adults-with-type-2-diabeteshttps://www.pharmacytimes.com/view/ada-2026-clinical-pharmacist-led-group-sessions-show-promise-for-hypoglycemia-prevention-in-older-adults-with-type-2-diabetes<![CDATA[ADA data show CGM plus pharmacist groups helps seniors with type 2 diabetes prevent hypoglycemia, boost confidence, and prompt safer meds.]]>Fri, 05 Jun 2026 13:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/elranatamab-demonstrates-high-response-rates-and-manageable-safety-in-high-risk-smoldering-multiple-myelomahttps://www.pharmacytimes.com/view/elranatamab-demonstrates-high-response-rates-and-manageable-safety-in-high-risk-smoldering-multiple-myeloma<![CDATA[Elranatamab monotherapy produced a 92% overall response rate and a 45% complete response rate in patients with high-risk smoldering multiple myeloma, supporting the potential of BCMA-directed bispecific antibody therapy as an early intervention strategy before progression to active disease.]]>Fri, 05 Jun 2026 13:24:42 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/closing-the-knowledge-gap-what-community-pharmacists-need-to-know-about-menopausehttps://www.pharmacytimes.com/view/closing-the-knowledge-gap-what-community-pharmacists-need-to-know-about-menopause<![CDATA[Discover how community pharmacists can spot menopause beyond hot flashes, avoid HRT mix-up myths, and collaborate on safe, updated treatments.]]>Fri, 05 Jun 2026 12:03:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-hot-flashes-how-our-understanding-of-menopause-and-vms-has-evolvedhttps://www.pharmacytimes.com/view/beyond-hot-flashes-how-our-understanding-of-menopause-and-vms-has-evolved<![CDATA[Learn how menopause VMS stem from the brain, last years, affect heart risk, and when hormone therapy is considered safe.]]>Fri, 05 Jun 2026 12:01:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/subcutaneous-isatuximab-on-body-injector-shows-high-reliability-favorable-safety-across-multiple-myeloma-trialshttps://www.pharmacytimes.com/view/subcutaneous-isatuximab-on-body-injector-shows-high-reliability-favorable-safety-across-multiple-myeloma-trials<![CDATA[Cross-trial data from more than 6000 administrations show that a subcutaneous isatuximab on-body injector was highly reliable and well tolerated.]]>Thu, 04 Jun 2026 19:39:37 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/real-world-use-of-talazoparib-plus-enzalutamide-and-hr-testing-trends-in-prostate-cancerhttps://www.pharmacytimes.com/view/real-world-use-of-talazoparib-plus-enzalutamide-and-hr-testing-trends-in-prostate-cancer<![CDATA[Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.]]>Thu, 04 Jun 2026 19:17:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/iberdomide-based-quadruplet-induction-followed-by-maintenance-achieves-high-response-and-mrd-negativity-in-ndmmhttps://www.pharmacytimes.com/view/iberdomide-based-quadruplet-induction-followed-by-maintenance-achieves-high-response-and-mrd-negativity-in-ndmm<![CDATA[IDEAL trial data show iberdomide quadruplet therapy drives high response rates and rising MRD negativity in newly diagnosed multiple myeloma.]]>Thu, 04 Jun 2026 19:12:50 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/teclistamab-monotherapy-demonstrates-significant-survival-and-response-benefits-versus-standard-regimens-in-rrmmhttps://www.pharmacytimes.com/view/teclistamab-monotherapy-demonstrates-significant-survival-and-response-benefits-versus-standard-regimens-in-rrmm<![CDATA[Phase 3 MajesTEC-9 data show that teclistamab monotherapy significantly improved PFS, OS, and depth of response compared with standard PVd or Kd regimens.]]>Thu, 04 Jun 2026 18:52:18 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-meanshttps://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means<![CDATA[The policy direction is clear, but the regulatory mechanics are still working their way through the system.]]>Thu, 04 Jun 2026 17:44:25 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/oncology-pulse-points-asco-living-guideline-updates-in-metastatic-castration-resistant-prostate-cancerhttps://www.pharmacytimes.com/view/oncology-pulse-points-asco-living-guideline-updates-in-metastatic-castration-resistant-prostate-cancer<![CDATA[Christine Barrett, PharmD, BCOP discusses key updates to the Systemic Treatment of Thyroid Cancer: ASCO Guideline.]]>Thu, 04 Jun 2026 15:57:43 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/collaboration-innovation-stewardship-and-the-future-of-infectious-diseases-pharmacotherapy-and-practicehttps://www.pharmacytimes.com/view/collaboration-innovation-stewardship-and-the-future-of-infectious-diseases-pharmacotherapy-and-practice<![CDATA[The inaugural Joint MAD-ID/SIDP Annual Meeting was a celebration of learning and networking and focused on the educational needs of infectious diseases pharmacist specialists.]]>Thu, 04 Jun 2026 13:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/alzheimer-updates-stroke-breakthroughs-and-the-case-for-early-treatmenthttps://www.pharmacytimes.com/view/alzheimer-updates-stroke-breakthroughs-and-the-case-for-early-treatment<![CDATA[Erica Marini, PharmD, and guest, Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments including a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on anti-amyloid therapies.]]>Thu, 04 Jun 2026 13:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/the-evolving-role-of-pharmacists-in-cardiovascular-disease-management-insights-and-future-perspectiveshttps://www.pharmacytimes.com/view/the-evolving-role-of-pharmacists-in-cardiovascular-disease-management-insights-and-future-perspectives<![CDATA[Pharmacists step into cardiovascular prevention with patient education, statin protocols, and new prescribing training—if clinical work gets paid.]]>Thu, 04 Jun 2026 12:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/darovasertib-plus-crizotinib-shows-striking-efficacy-in-hla-a2-negative-metastatic-uveal-melanoma-optimum-02-results-showhttps://www.pharmacytimes.com/view/darovasertib-plus-crizotinib-shows-striking-efficacy-in-hla-a2-negative-metastatic-uveal-melanoma-optimum-02-results-show<![CDATA[Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.]]>Wed, 03 Jun 2026 20:55:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/camizestrant-plus-cdk4-6-inhibitor-demonstrates-sustained-benefit-beyond-first-progression-in-esr1-mutated-breast-cancerhttps://www.pharmacytimes.com/view/camizestrant-plus-cdk4-6-inhibitor-demonstrates-sustained-benefit-beyond-first-progression-in-esr1-mutated-breast-cancer<![CDATA[SERENA-6 shows early switch to oral SERD camizestrant plus CDK4/6 inhibitor improves PFS2, delays chemotherapy, and preserves quality of life.]]>Wed, 03 Jun 2026 19:57:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-grants-priority-review-to-bezuclastinib-plus-sunitinib-for-patients-with-advanced-gisthttps://www.pharmacytimes.com/view/fda-grants-priority-review-to-bezuclastinib-plus-sunitinib-for-patients-with-advanced-gist<![CDATA[The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).]]>Wed, 03 Jun 2026 19:32:55 GMTPharmacy TimesusPharmacy Times Articles